These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8038458

  • 21. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 22. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
    Bellamy WT, Odeleye A, Huizenga E, Dalton WS, Weinstein RS, Grogan TM.
    Clin Cancer Res; 1995 Dec 01; 1(12):1563-70. PubMed ID: 9815957
    [Abstract] [Full Text] [Related]

  • 23. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD.
    Clin Cancer Res; 2001 Sep 01; 7(9):2862-9. PubMed ID: 11555604
    [Abstract] [Full Text] [Related]

  • 24. [Establishment of EL4 tumor-bearing mouse models and investigation on immunological mechanisms of anti-tumor effect of melphalan].
    Li ML, Li CG, Shu XH, Jia YJ, Qin ZH.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Mar 01; 22(2):235-8. PubMed ID: 16507262
    [Abstract] [Full Text] [Related]

  • 25. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 26. Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment.
    Tomazic V, Ehrke MJ, Mihich E.
    Cancer Res; 1981 Sep 01; 41(9 Pt 1):3370-6. PubMed ID: 7260903
    [Abstract] [Full Text] [Related]

  • 27. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL, Roberts D.
    Cancer Res; 1977 Mar 01; 37(3):678-83. PubMed ID: 837368
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
    Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A.
    Clin Cancer Res; 1999 Mar 01; 5(3):687-93. PubMed ID: 10100723
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK.
    Cancer Res; 1994 May 15; 54(10):2688-94. PubMed ID: 8168098
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
    Wu B, Shen RN, Wang WX, Broxmeyer HE, Lu L.
    Stem Cells; 1993 Sep 15; 11(5):412-21. PubMed ID: 8241952
    [Abstract] [Full Text] [Related]

  • 34. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.
    Krawczyk CM, Verstovsek S, Ujházy P, Maccubbin D, Ehrke MJ.
    Cancer Immunol Immunother; 1995 Jun 15; 40(6):347-57. PubMed ID: 7627991
    [Abstract] [Full Text] [Related]

  • 35. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1994 Jan 15; 424():1-304. PubMed ID: 12616287
    [Abstract] [Full Text] [Related]

  • 36. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
    Leto G, Tumminello FM, Gebbia N, Woynarowska B, Bernacki RJ.
    Anticancer Res; 1990 Jan 15; 10(1):265-9. PubMed ID: 2334138
    [Abstract] [Full Text] [Related]

  • 37. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K.
    Clin Cancer Res; 1999 Jul 15; 5(7):1905-17. PubMed ID: 10430098
    [Abstract] [Full Text] [Related]

  • 38. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A, Gamboa G, Nasseri A, Podnos YD, Emma D, Dorion G, Rawlings L, Carpenter PM, Bustamante A, Patel J, Rideout D.
    Gynecol Oncol; 1996 Feb 15; 60(2):203-12. PubMed ID: 8631539
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.